Clinical Trials
54 trialsA Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline
IROCAS
UNICANCER
DeFianCe
Leap Therapeutics, Inc.
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
City of Hope Medical Center
FOxTROT2France
Centre Hospitalier Universitaire Dijon
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
CLAUDIA
Seoul National University Hospital
IDEA
GERCOR - Multidisciplinary Oncology Cooperative Group
PePiTA
Jules Bordet Institute
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
PROMENADE
University of Roma La Sapienza
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
NeoFox
WntResearch AB
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Sun Yat-sen University
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
Medical Research Council
DEBIRI
University of Louisville
CCRe-IV
Hospital Universitari de Bellvitge
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
UNICANCER
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
UNICANCER
JSFOL
Xiangya Hospital of Central South University
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
Federation Francophone de Cancerologie Digestive
1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Brown University
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Adjuvant Chemotherapy in High Risk Stage II Colon Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CUFOX
University of Leicester
SIRFLOX
Sirtex Medical
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer
The First Affiliated Hospital with Nanjing Medical University
Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
Memorial Sloan Kettering Cancer Center
TOSCA
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NYU Langone Health